Niche blockbusters: the next drug cost crisis?

For quite a while –especially in the 1990s and early 2000s– rising drug costs were a major driver of medical inflation. Big pharma was rolling out lots of “me too” products in existing drug classes –such as statins (e.g., Lipitor) and COX-2 inhibitors (e.g., Vioxx)– that could be prescribed widely. In a normal market, having [...]

Source: http://feedproxy.google.com/~r/HealthBusinessBlog/~3/KsNg2Y4ix8Y/

discovery health channel arab health